Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: A meta-analysis of 22 phase III randomized controlled trials

Respiratory Medicine

Volumn 107, Issue 8, 2013, Pages 1280-1283

  Qi, Wei Xiang ^a   Tang, Li Na ^a   He, Ai Na ^a   Yao, Yang ^a   Shen, Zan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cancer; EGFR TKIs; Erlotinib; Fatal adverse events; Gefitinib; Meta analysis

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; NERATINIB;

ARTERY THROMBOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA; NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK ASSESSMENT; SYSTEMATIC REVIEW; VEIN THROMBOSIS;

EID: 84880846133     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.06.005     Document Type: Article

References (20)

1. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 2005 341 354 (Pubitemid 40637826)
2. B. Gori, S. Ricciardi, and A. Fulvi New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment Future Oncol 8 2012 559 573
3. M.H. Cohen, J.R. Johnson, and S. Chattopadhyay Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC) Oncologist 15 2010 1344 1351
4. M.H. Cohen, G.A. Williams, and R. Sridhara United States food and drug administration drug approval summary: gefitinib (ZD1839; Iressa) tablets Clin Cancer Res 10 2004 1212 1218 (Pubitemid 38365209)
5. M.H. Cohen, G.A. Williams, and R. Sridhara FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets Oncologist 8 2003 303 306 (Pubitemid 36929716)
6. A. Awada, L. Dirix, and L. Manso Sanchez Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy Ann Oncol 24 2013 109 116
7. Y. Ito, M. Suenaga, and K. Hatake Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a phase 1 dose-escalation study Jpn J Clin Oncol 42 2012 278 286
8. Y.C. Tsai, C.H. Yeh, and K.Y. Tzen Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma Eur J Cancer 49 6 2013 Apr 1458 1466
9. M. Schuler, A. Awada, and P. Harter A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer Breast Cancer Res Treat 134 2012 1149 1159
10. V.A. Miller, V. Hirsh, and J. Cadranel Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Lancet Oncol 13 2012 528 538
11. R.B. Natale, S. Thongprasert, and F.A. Greco Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 29 2011 1059 1066
12. T. Suzumura, T. Kimura, and S. Kudoh Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer BMC Cancer 12 2012 568
13. W.X. Qi, Z. Shen, and F. Lin Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis Asian Pac J Cancer Prev 13 2012 5177 5182
14. F. Petrelli, M. Cabiddu, K. Borgonovo, and S. Barni Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials Ann Oncol 23 7 2012 Jul 1672 1679
15. U. Gatzemeier, A. Pluzanska, and A. Szczesna Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552 (Pubitemid 46733081)
16. L. Crino, F. Cappuzzo, and P. Zatloukal Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study J Clin Oncol 26 2008 4253 4260
17. D. Moher, B. Pham, and A. Jones Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352 1998 609 613 (Pubitemid 28380142)
18. NCI, Cancer Therapy Evaluation Program. CTC v. 2.0 and common terminology criteria for adverse events criteria V3.0 (CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm.
19. T.K. Choueiri, F.A. Schutz, and Y. Je Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials J Clin Oncol 28 2010 2280 2285
20. E. Zintzaras, and J.P. Ioannidis Heterogeneity testing in meta-analysis of genome searches Genet Epidemiol 28 2005 123 137